cell immunotherapy

Oncology

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.

Events

Partner Content

Achieving Standardization & Operational Excellence in Vein-to-Vein Supply

News

BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.